US Stock Insider Trading | OmniAb Discloses 3 Insider Transactions on February 17

On February 17, 2026, OmniAb (OABI) disclosed three insider trading transactions. Director FOEHR MATTHEW W sold 20,800 shares on February 17, 2026.

[Recent Insider Transactions]

[Company Information]

OmniAb, Inc. was incorporated on December 14, 2015, under Delaware law. OmniAb’s discovery platform provides pharmaceutical partners with access to various antibody libraries and high-throughput screening technologies, enabling the discovery of next-generation therapeutics. The core of the OmniAb platform is their proprietary transgenic animals’ Biological Intelligence (BI), including OmniRat, OmniChicken, and OmniMouse, which are genetically engineered to produce antibodies with human sequences, facilitating the development of human therapeutic candidates. OmniFlic (transgenic rats) and OmniClic (transgenic chickens) meet industry demand for bispecific antibodies through a common light chain approach, while OmniTaur features bovine antibodies with unique structural properties for complex targets. Established core capabilities focused on ion channels and transporters further differentiate their technology and create opportunities in emerging target categories. OmniAb antibodies have been used in various formats, including bispecific antibodies and antibody-drug conjugates. The OmniAb technology suite covers everything from BI-driven library generation to advanced antibody discovery and optimization, providing an efficient and customizable end-to-end solution for the growing global pharmaceutical discovery industry.